Submission of New Drug Application for Paltusotine for the Treatment of AcromegalyCompleted Upsized Public Offering of $575M of Common Stock ...

The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Announced that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) seeking ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

In October 2024, we provided updated results from our IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune ® HPV and chemoradiotherapy presented at the ...

Daré will host a conference call and live webcast today, November 14, 2024, at 4:30 p.m. Eastern Time to review financial ...

Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. S1P receptors are located throughout the body, including the ...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate - pivotal Phase 3 contra ...

and information on how to submit an investigational new drug (IND) application to administer an investigational product to humans. The staff of CAB and MATTB comprises consumer safety officers ...

Recent positive Type C meeting with the U.S. Food and Drug Administration (FDA) confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full ...